MARIANNE Update: T-DM1 Does Not Significantly Improve Survival in HER2+ Breast Cancer

Share this content:
The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.
The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival (OS) compared with trastuzumab and a taxane (HT), according to final data from the phase 3 MARIANNE study (ClinicalTrials.gov Identifier: NCT01120184) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

Carlos Barrios, MD, presented these data on behalf of Edith Perez, MD, the study investigator.

Women enrolled in the study had centrally assessed HER2+ progressive/recurrent locally advanced breast cancer or untreated metastatic breast cancer (MBC) with at least a 6-month interval since treatment with a taxane or a vinca alkaloid.

MARIANNE had shown that T-DM1 alone or in combination with pertuzumab does not improve progression-free survival (PFS) compared with HT in this setting.

The present OS analysis of MARIANNE shows a similar trend to the PFS data. At the cut-off date of May 2016, after a median follow up of 54 months, median OS was 50.9, 53.7, and 51.8 months for HT (365 patients), T-DM1 (367 patients), and T-BM1 plus pertuzumab (363 patients), respectively. Comparisons of the T-DM1 arms with HT were not significant.

Similar observations were noted when patients who received T-DM1 and/or pertuzumab after progressing on HT were censored from the analysis. Dr Barrios noted that there was no subgroup of patients in whom OS was significant in any of the T-DM1 arms.

Grade 3 to 5 adverse events (AEs) were seen less frequently among patients who received T-DM1. Grade 3 to 5 neutropenia was highest in patients on HT (19.3% vs 4.4% for T-DM1 vs 3.8% for T-DM1 + pertuzumab). 

RELATED: TREnd: Adding Palbociclib to Endocrine Therapy Provides Clinical Benefits in Breast Cancer

While the median OS was similar across treatment arms, a median OS of 53.7 months and fewer grade 3 or worse AEs (vs other arms) supports T-DM1 as an effective and alternative first-line treatment for HER2-positive patients with MBC, Dr Barrios concluded.

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Perez EA, Barrios CH, Eiermann W, et al. Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± oeruzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE. J Clin Oncol. 2017;34(suppl; abstr 1003).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs